Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis
CClin Gastroenterol Hepatol 2023;22:961-970.e12
The results of this study show that anti-IL-12/23, JAK inhibitors, and anti-TNF-α were associated with slightly higher risk of MACE compared with placebo. The risk was no different between biologic treatments, and the magnitude of risk did not differ between IMID type.
This meta-analysis by Mattay, et al. included 40 studies and compared MACE incidence between IMID patients treated with JAKi, anti-TNFs, anti-IL-23, anti-IL-12/23, and placebo.
Keywords:
